SIMRITPARMARSIMRIT PARMAR9180PARMAR, SIMRITAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:hasResearchArearesearch areasInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast namePerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1728027Authorship 1749651Authorship 17986614Authorship 1845461Authorship 18456210Authorship 1860677Authorship 1869331Authorship 1877123Authorship 18772618Authorship 1904215Authorship 1909951Authorship 1918695Authorship 19203712Authorship 19228919Authorship 1923486Authorship 19238019Authorship 19245612Authorship 1926976Authorship 1933818Authorship 19346511Authorship 1941041Authorship 19449615Authorship 195123112805378Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmar S, Giafis N, Kalvakolanu DV, Rahman A, Uddin S, Minucci S, Tallman MS, Fish EN, Platanias LCThe Journal of biological chemistryActivation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem. 2003 Aug 29; 278(35):32544-51.J Biol Chem2003-06-12T00:00:002003Activation of protein kinase C delta by all-trans-retinoic acid.15790787Parmar S, Smith J, Sassano A, Uddin S, Katsoulidis E, Majchrzak B, Kambhampati S, Eklund EA, Tallman MS, Fish EN, Platanias LCBloodDifferential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood. 2005 Oct 01; 106(7):2436-43.Blood2005-03-24T00:00:002005Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.18474728Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, Das B, Kapoun AM, Navas TA, Parmar S, Kambhampati S, Pellagatti A, Braunchweig I, Zhang Y, Wickrema A, Medicherla S, Boultwood J, Platanias LC, Higgins LS, List AF, Bitzer M, Verma ABloodInhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008 Oct 15; 112(8):3434-43.Blood2008-05-12T00:00:002008Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.19672773Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, Schuster K, Verma AK, Terada LS, Platanias LC, Parmar SLeukemia & lymphomaActivation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma. 2009 Dec; 50(12):2017-29.Leuk Lymphoma2009-12-01T00:00:002009Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.22750645Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationClofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1819-26.Biol Blood Marrow Transplant2012-06-29T00:00:002012Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.22780206Parmar S, Iyer SPExpert review of hematologyBridging the gap in hematological malignancies. Expert Rev Hematol. 2012 Jun; 5(3):257-9.Expert Rev Hematol2012-06-01T00:00:002012Bridging the gap in hematological malignancies.23032694Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AFLeukemiaRandomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr; 27(4):977-80.Leukemia2012-09-11T00:00:002012Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.23220013Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt SBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationDose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biol Blood Marrow Transplant. 2013 Mar; 19(3):474-80.Biol Blood Marrow Transplant2012-12-07T00:00:002012Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.RICHARD ECHAMPLINRICHARD E CHAMPLIN8508CHAMPLIN, RICHARD EProfessorELIZABETHSHPALLELIZABETH SHPALL9025SHPALL, ELIZABETHProfessorQAISERBASHIRQAISER BASHIR9601BASHIR, QAISERAssociate ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessor2.660580.00679229497research areas4.244520.0247233101coauthor of205.39621.009560similar to11135selected publicationsUDAY RPOPATUDAY R POPAT8670POPAT, UDAY RProfessorMUZAFFAR HQAZILBASHMUZAFFAR H QAZILBASH9055QAZILBASH, MUZAFFAR HProfessorAuthorship 2206111Authorship 2209986Authorship 2220478Authorship 2290614Authorship 23000613Authorship 2305148Authorship 23226716Authorship 2342621115234567Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, Frater JL, Tallman MSLeukemia researchPhase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res. 2004 Sep; 28(9):909-19.Leuk Res2004-09-01T00:00:002004Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.15471950Lal L, Li Y, Smith J, Sassano A, Uddin S, Parmar S, Tallman MS, Minucci S, Hay N, Platanias LCBloodActivation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 2005 Feb 15; 105(4):1669-77.Blood2004-10-07T00:00:002004Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells.16204077Katsoulidis E, Li Y, Yoon P, Sassano A, Altman J, Kannan-Thulasiraman P, Balasubramanian L, Parmar S, Varga J, Tallman MS, Verma A, Platanias LCCancer researchRole of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res. 2005 Oct 01; 65(19):9029-37.Cancer Res2005-10-01T00:00:002005Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.21326157Bashir Q, Robinson SN, de Lima MJ, Parmar S, Shpall EClinical advances in hematology & oncology : H&OUmbilical cord blood transplantation. Clin Adv Hematol Oncol. 2010 Nov; 8(11):786-801.Clin Adv Hematol Oncol2010-11-01T00:00:002010Umbilical cord blood transplantation.21532034Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kambhampati S, Parmar S, Nischal S, Hueck C, Suzuki M, Freidman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, McMahon C, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma AThe Journal of biological chemistryAberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem. 2011 Jul 15; 286(28):25211-23.J Biol Chem2011-04-30T00:00:002011Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.21887685Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MHCancerA randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15.Cancer2011-09-01T00:00:002011A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.23345254Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima MAmerican journal of hematologyAllogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200.Am J Hematol2013-01-24T00:00:002013Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.24270737Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero GLeukemiaExpression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.Leukemia2013-11-25T00:00:002013Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.Authorship 2424494Authorship 2444583Authorship 2459914Authorship 2461611Authorship 2483427Authorship 2533342Authorship 2544361Authorship 2546973Authorship 2576031Authorship 2602988Authorship 2613367Authorship 261415111342431Mahmud N, Devine SM, Weller KP, Parmar S, Sturgeon C, Nelson MC, Hewett T, Hoffman RBloodThe relative quiescence of hematopoietic stem cells in nonhuman primates. Blood. 2001 May 15; 97(10):3061-8.Blood2001-05-15T00:00:002001The relative quiescence of hematopoietic stem cells in nonhuman primates.12884916Verma A, Kambhampati S, Parmar S, Platanias LCCancer metastasis reviewsJak family of kinases in cancer. Cancer Metastasis Rev. 2003 Dec; 22(4):423-34.Cancer Metastasis Rev2003-12-01T00:00:002003Jak family of kinases in cancer.15056660Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LCThe Journal of biological chemistryRole of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem. 2004 Jun 11; 279(24):25345-52.J Biol Chem2004-03-31T00:00:002004Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.15512805Kambhampati S, Verma A, Li Y, Parmar S, Sassano A, Platanias LCLeukemia & lymphomaSignalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leuk Lymphoma. 2004 Nov; 45(11):2175-85.Leuk Lymphoma2004-11-01T00:00:002004Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells.16940419Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, Kerr I, Nguyen AN, Xu Y, Platanias LC, List AA, Higgins LS, Verma ABloodInhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006 Dec 15; 108(13):4170-7.Blood2006-08-29T00:00:002006Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.19857589Parmar S, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHematopoietic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S37-44.Biol Blood Marrow Transplant2009-10-24T00:00:002009Hematopoietic stem cell transplantation for myelodysplastic syndrome.20196692Kelly SS, Parmar S, De Lima M, Robinson S, Shpall ECytotherapyOvercoming the barriers to umbilical cord blood transplantation. Cytotherapy. 2010 Apr; 12(2):121-30.Cytotherapy2010-04-01T00:00:002010Overcoming the barriers to umbilical cord blood transplantation.21060030Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MHJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrimary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol. 2011 Feb 01; 29(4):e79-80.J Clin Oncol2010-11-08T00:00:002010Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection.21943676Parmar S, de Lima M, Deeg HJ, Champlin RSeminars in oncologyHematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol. 2011 Oct; 38(5):693-704.Semin Oncol2011-10-01T00:00:002011Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.23733001Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1227-32.Biol Blood Marrow Transplant2013-05-31T00:00:002013Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.23872222Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationA randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.Biol Blood Marrow Transplant2013-07-17T00:00:002013A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.24534447Parmar S, Ritchie DSCurrent opinion in immunologyAllogeneic transplantation as anticancer immunotherapy. Curr Opin Immunol. 2014 Apr; 27:38-45.Curr Opin Immunol2014-02-15T00:00:002014Allogeneic transplantation as anticancer immunotherapy.Authorship 2652262Authorship 2661291Authorship 2705795Authorship 2714521312888932Kwaan HC, Parmar S, Wang JSeminars in thrombosis and hemostasisPathogenesis of increased risk of thrombosis in cancer. Semin Thromb Hemost. 2003 Jun; 29(3):283-90.Semin Thromb Hemost2003-06-01T00:00:002003Pathogenesis of increased risk of thrombosis in cancer.16260858Parmar S, Rademaker AW, Fung BB, Kozlowski JM, Kuzel TMMedical oncology (Northwood, London, England)Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience. Med Oncol. 2005; 22(4):399-405.Med Oncol2005-01-01T00:00:002005Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience.22242817Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MHLeukemia & lymphomaDurable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1525-9.Leuk Lymphoma2012-03-01T00:00:002012Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.23330820Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat UBritish journal of haematologyIncidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013 Mar; 160(6):798-805.Br J Haematol2013-01-18T00:00:002013Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation.25778529Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJBloodEnforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.Blood2015-03-16T00:00:002015Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.Authorship 2732202Authorship 274162115850832Kaur S, Parmar S, Smith J, Katsoulidis E, Li Y, Sassano A, Majchrzak B, Uddin S, Tallman MS, Fish EN, Platanias LCExperimental hematologyRole of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol. 2005 May; 33(5):550-7.Exp Hematol2005-05-01T00:00:002005Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells.21245756Parmar S, Fernandez-Vina M, de Lima MCurrent opinion in hematologyNovel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia. Curr Opin Hematol. 2011 Mar; 18(2):98-104.Curr Opin Hematol2011-03-01T00:00:002011Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia.Authorship 27963611Authorship 28976210Authorship 2929851Authorship 2953597Authorship 29611910Authorship 29666716Authorship 2979748Authorship 29864114Authorship 3025087Authorship 30254312Authorship 303436624882259Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MHLeukemia & lymphomaShort-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma. 2015 Feb; 56(2):533-5.Leuk Lymphoma2014-07-15T00:00:002014Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.25428215Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Shpall EJBloodEx vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood. 2015 Feb 26; 125(9):1502-6.Blood2014-11-26T00:00:002014Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.25708219Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationGeneral and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1284-90.Biol Blood Marrow Transplant2015-02-20T00:00:002015General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation.25801490Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi FAmerican journal of hematologyClonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol. 2015 Jul; 90(7):E134-5.Am J Hematol2015-07-01T00:00:002015Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission.25842049Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1413-7.Biol Blood Marrow Transplant2015-04-02T00:00:002015Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.25867648Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin RBone marrow transplantationLeukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant. 2015 Jul; 50(7):939-946.Bone Marrow Transplant2015-04-13T00:00:002015Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.25963284El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir QClinical lymphoma, myeloma & leukemiaAutologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):472-6.Clin Lymphoma Myeloma Leuk2015-03-27T00:00:002015Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.26250579Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fern?ndez-Vi?a M, Champlin RE, Shpall EJHaematologicaBetter allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.Haematologica2015-08-06T00:00:002015Better allele-level matching improves transplant-related mortality after double cord blood transplantation.26361647Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir QClinical lymphoma, myeloma & leukemiaOutcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):687-93.Clin Lymphoma Myeloma Leuk2015-08-05T00:00:002015Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.26697430Mehta RS, Rezvani K, Olson A, Oran B, Hosing C, Shah N, Parmar S, Armitage S, Shpall EJFrontiers in medicineNovel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne). 2015; 2:89.Front Med (Lausanne)2015-12-11T00:00:002015Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials.26702475Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MHClinical lymphoma, myeloma & leukemiaOutcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42.Clin Lymphoma Myeloma Leuk2015-12-01T00:00:002015Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.27247137Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani KBloodSpecific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312.Blood2016-05-31T00:00:002016Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.74Professor14Associate Professor27420405Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MHAmerican journal of hematologyOutcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016 10; 91(10):E442-7.Am J Hematol2016-09-03T00:00:002016Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.22643322Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RBBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHigh-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86.Biol Blood Marrow Transplant2012-05-27T00:00:002012High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.27677740Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KNLeukemiaBET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 03; 31(3):678-687.Leukemia2016-09-28T00:00:002016BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.21350559Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O'Brien S, Fernandez-Vi?a M, Shpall EJ, Wierda WGLeukemiaHLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. Leukemia. 2011 Jun; 25(6):1036-9.Leukemia2011-02-25T00:00:002011HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance.23128322Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RBBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAutologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7.Biol Blood Marrow Transplant2012-11-02T00:00:002012Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.Authorship 842245Authorship 845345Authorship 846693Authorship 846955Authorship 846956Authorship 847369Authorship 847841Authorship 849367Authorship 849631Authorship 850245Authorship 850455Authorship 851673Authorship 853331Authorship 854287Authorship 855827Authorship 855868Authorship 861138Authorship 861898Authorship 866908Authorship 867356Authorship 867934Biology of Blood and Marrow TransplantationGeneral and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation. 21:1284-1290.General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood TransplantationBone Marrow TransplantationOutcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplantation. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantationBone Marrow TransplantationFludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patientsCancerProlonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myelomaLeukemia and LymphomaShort-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leukemia and Lymphoma. 56:533-535.Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myelomaClinical Lymphoma, Myeloma and LeukemiaOutcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clinical Lymphoma, Myeloma and Leukemia. 15:687-693.Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantationClinical Lymphoma, Myeloma and LeukemiaAutologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia. 15:472-476.Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma PatientsJournal of the American College of RadiologyUse of an Online Education Platform to Enhance Patients' Knowledge About Radiation in Diagnostic Imaging. Journal of the American College of Radiology. Use of an Online Education Platform to Enhance Patients' Knowledge About Radiation in Diagnostic ImagingBone Marrow TransplantationLeukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation. 50:939-946.Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantationBloodMHC class I chain-related gene a (MICA) in unrelated donor transplantation. Blood. 114:4754-4756.MHC class I chain-related gene a (MICA) in unrelated donor transplantationBiology of Blood and Marrow TransplantationOutcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andSoft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21:1413-1417.Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andSoft Tissue Involvement after Autologous Hematopoietic Stem Cell TransplantationLeukemia and LymphomaDouble umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leukemia and Lymphoma. 1-9.Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphomaLeukemiaBET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cellsBone Marrow TransplantationAutologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplantation. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvementClinical Lymphoma, Myeloma and LeukemiaOutcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationHaematologicaBetter allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 100:1361-1370.Better allele-level matching improves transplant-related mortality after double cord blood transplantationBiology of Blood and Marrow TransplantationPure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation. 22:961-965.Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe PancytopeniaSao Paulo Medical JournalCondutas hematológicas perante o mieloma múltiplo. Sao Paulo Medical Journal. 134:335-341.Condutas hematológicas perante o mieloma múltiplo22796535Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImproved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.Biol Blood Marrow Transplant2012-07-11T00:00:002012Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.Leukemia and LymphomaAsia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference. Leukemia and Lymphoma. 1-5.Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies ConferenceBone Marrow TransplantationUmbilical cord blood graft engineering. Bone Marrow Transplantation. 50:S55-S62.Umbilical cord blood graft engineeringBloodSpecific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 128:297-312.Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation23284688Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WGPloS oneGeneration of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One. 2012; 7(12):e51390.PLoS One2012-12-19T00:00:002012Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.28295190Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJBritish journal of haematologyPhase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.Br J Haematol2017-03-14T00:00:002017Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.28522110Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash MThe Lancet. HaematologyHigh-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292.Lancet Haematol2017-05-15T00:00:002017High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.21646477Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJCancer researchEx vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res. 2011 Jul 15; 71(14):5040-9.Cancer Res2011-06-06T00:00:002011Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.23234514de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJThe New England journal of medicineCord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.N Engl J Med2012-12-13T00:00:002012Cord-blood engraftment with ex vivo mesenchymal-cell coculture.D009101Disorders36221390.432145Multiple MyelomaAuthorship 88700612Authorship 88787412Authorship 88803314Authorship 88806310Authorship 88886926Authorship 88898511D018380Procedures55965180.273586Hematopoietic Stem Cell TransplantationD050378Anatomy3036690.711522T-Lymphocytes, RegulatoryD019172Procedures21822240.514921Transplantation ConditioningAuthorship 9054521Authorship 90653716Authorship 9066215Authorship 9089321Authorship 9103174Authorship 9106548Authorship 91294611Authorship 91467411Authorship 91552217Authorship 9171926Authorship 9175028Authorship 9179257Authorship 9199677Authorship 9223988Authorship 92564111Authorship 92599941Authorship 92928818Authorship 93331714Authorship 9346573Authorship 93481221Authorship 9351828Authorship 93687711Authorship 93748822Authorship 9379392Authorship 9397113Authorship 9403532226472485Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CMLeukemia & lymphomaDouble umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15.Leuk Lymphoma2015-12-23T00:00:002015Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.26773409Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MHEuropean journal of haematologyOutcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol. 2016 Oct; 97(4):342-7.Eur J Haematol2016-02-15T00:00:002016Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.26887657Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim CSLeukemia & lymphomaAsia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma. 2016 07; 57(7):1534-8.Leuk Lymphoma2016-02-17T00:00:002016Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China.26917738Parmar S, Shpall EJBloodTreg adoptive therapy: is more better? Blood. 2016 Feb 25; 127(8):962-3.Blood2016-02-25T00:00:002016Treg adoptive therapy: is more better?26921820Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat UBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5.Biol Blood Marrow Transplant2016-02-26T00:00:002016Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.27557143Kerbauy LN, Parmar S, Kutner JM, Gusm?o BM, Hamerschlak NSao Paulo medical journal = Revista paulista de medicinaHematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study. Sao Paulo Med J. 2016 Jul-Aug; 134(4):335-41.Sao Paulo Med J2016-07-01T00:00:002016Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study.28111051Steele JR, Jones AK, Clarke RK, Shiao SJ, Wei W, Shoemaker S, Parmar SJournal of the American College of Radiology : JACRUse of an Online Education Platform to Enhance Patients' Knowledge About Radiation in Diagnostic Imaging. J Am Coll Radiol. 2017 Mar; 14(3):386-392.J Am Coll Radiol2017-01-20T00:00:002017Use of an Online Education Platform to Enhance Patients' Knowledge About Radiation in Diagnostic Imaging.27680710Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir QCancerProlonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837.Cancer2016-09-28T00:00:002016Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.28295181Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CMBritish journal of haematologyLong-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.Br J Haematol2017-03-14T00:00:002017Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.28351938Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SOBloodPredictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 06 01; 129(22):3031-3033.Blood2017-03-28T00:00:002017Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.28404929Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil SOncotargetHematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget. 2017 Jun 20; 8(25):41620-41630.Oncotarget2017-06-20T00:00:002017Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.28506845Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran BBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEx Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1359-1366.Biol Blood Marrow Transplant2017-05-12T00:00:002017Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.28513828Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir QCancerOutcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.Cancer2017-05-17T00:00:002017Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.28850699Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia TAmerican journal of hematologyClinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302.Am J Hematol2017-09-25T00:00:002017Clinical outcomes in adult patients with aplastic anemia: A single institution experience.28918304Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHaploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.Biol Blood Marrow Transplant2017-09-14T00:00:002017Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.28895206Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash MEuropean journal of haematologyInpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. 2017 Dec; 99(6):532-535.Eur J Haematol2017-10-08T00:00:002017Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.29721054Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WAJournal of CancerInternational Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.J Cancer2018-04-06T00:00:002018International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.30258129Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SOBone marrow transplantationImpact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019 06; 54(6):839-848.Bone Marrow Transplant2018-09-26T00:00:002018Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.30263095Kellner JN, Yvon E, Parmar SOncotargetEx vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen. Oncotarget. 2018 Sep 14; 9(72):33694-33701.Oncotarget2018-09-14T00:00:002018Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen.30337700Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SOBone marrow transplantationPilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 04; 54(4):601-606.Bone Marrow Transplant2018-10-18T00:00:002018Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.30016656Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2197-2203.Biol Blood Marrow Transplant2018-08-09T00:00:002018Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.30479692Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar SOncotargetThird party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018 Nov 02; 9(86):35611-35622.Oncotarget2018-11-02T00:00:002018Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution.30389035Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BSThe Lancet. HaematologyFludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.Lancet Haematol2018-11-01T00:00:002018Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.30628504Ma H, Padmanabhan Iyer S, Parmar S, Gong YLeukemia & lymphomaAdoptive cell therapy for acute myeloid leukemia. Leuk Lymphoma. 2019 06; 60(6):1370-1380.Leuk Lymphoma2019-01-10T00:00:002019Adoptive cell therapy for acute myeloid leukemia.30446740Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MHBone marrow transplantationPrimary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093.Bone Marrow Transplant2018-11-16T00:00:002018Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.30763728Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.Biol Blood Marrow Transplant2019-02-11T00:00:002019Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.D006086Disorders28926200.452414Graft vs Host DiseaseAuthorship 941584830639822Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationComparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044.Biol Blood Marrow Transplant2019-01-11T00:00:002019Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.Authorship 9432231130910541Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MHThe Lancet. HaematologyConditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.Lancet Haematol2019-03-22T00:00:002019Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.Authorship 945758331014360Ma H, Padmanabhan IS, Parmar S, Gong YJournal of hematology & oncologyTargeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol. 2019 04 24; 12(1):41.J Hematol Oncol2019-04-24T00:00:002019Targeting CLL-1 for acute myeloid leukemia therapy.19654407Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina MBloodDonor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood. 2009 Oct 01; 114(14):2884-7.Blood2009-08-04T00:00:002009Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.21149654Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyProphylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302.J Clin Oncol2010-12-13T00:00:002010Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.21780997Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MHLeukemia & lymphomaFeasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22.Leuk Lymphoma2011-08-24T00:00:002011Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma.22231283Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MHAmerican journal of hematologyPredictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6.Am J Hematol2012-01-09T00:00:002012Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.Authorship 9515781631288594Bowler TG, Pradhan K, Kong Y, Bartenstein M, Morrone KA, Sridharan A, Kessel RM, Shastri A, Giricz O, Bhagat TD, Gordon-Mitchell S, Rohanizadegan M, Hooda L, Datt I, Przychodzen BP, Parmar S, Maqbool S, Maciejewski JP, Steidl U, Greally JM, Verma ALeukemia & lymphomaMisidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions. Leuk Lymphoma. 2019 12; 60(13):3132-3137.Leuk Lymphoma2019-07-10T00:00:002019Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions.Authorship 9762351331971032Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SSLeukemia & lymphomaPretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma. 2020 06; 61(6):1380-1387.Leuk Lymphoma2020-01-23T00:00:002020Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.Authorship 9873771232291233Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CCClinical lymphoma, myeloma & leukemiaImaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk. 2020 08; 20(8):533-541.Clin Lymphoma Myeloma Leuk2020-02-20T00:00:002020Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission.Authorship 9930531532604096Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat URActa haematologicaCytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.Acta Haematol2020-06-30T00:00:002020Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.Authorship 9975561132822484Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TLBlood advancesClinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 08 25; 4(16):3943-3951.Blood Adv2020-08-25T00:00:002020Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.Authorship 10010531432990738Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BSJAMA network openAssessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020 09 01; 3(9):e2013935.JAMA Netw Open2020-09-01T00:00:002020Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy.Authorship 1010511933534891Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SSBloodPrognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021 06 10; 137(23):3272-3276.Blood2021-06-10T00:00:002021Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.Authorship 1015444933781521Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto YTransplantation and cellular therapyInfluence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.Transplant Cell Ther2020-12-20T00:00:002020Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma.Authorship 10177472233951890Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BSHaematologicaImproved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022 04 01; 107(4):899-908.Haematologica2022-04-01T00:00:002022Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.Authorship 10181261833965187Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat UTransplantation and cellular therapyEltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.Transplant Cell Ther2021-02-06T00:00:002021Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.Authorship 10251381534264268Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed SBlood advancesCRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.Blood Adv2021-07-27T00:00:002021CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.Authorship 10412751035230977Li L, Muftuoglu M, Liang S, Basyal M, Lv J, Akdogan ME, Chen K, Andreeff M, Flowers CR, Parmar SJCI insightIn-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight. 2022 04 08; 7(7).JCI Insight2022-04-08T00:00:002022In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals.Authorship 10451601035512184Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin JBloodRisk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 08 04; 140(5):504-515.Blood2022-08-04T00:00:002022Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.24094497Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Mart?n-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJCytotherapyFucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy. 2014 Jan; 16(1):84-9.Cytotherapy2013-10-01T00:00:002013Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment.24204673Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJPloS oneAntigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781.PLoS One2013-10-18T00:00:002013Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.Authorship 10465252235610308Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin REBone marrow transplantationA randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303.Bone Marrow Transplant2022-05-24T00:00:002022A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation.Authorship 10474101835687817Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MRBlood cancer discoveryFollicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov. 2022 09 06; 3(5):428-443.Blood Cancer Discov2022-09-06T00:00:002022Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.Authorship 10611901236437190Lyu MA, Huang M, Zeng K, Li L, Khoury JD, Nishimoto M, Ma H, Sadeghi T, Mukherjee S, Slutsky AS, Flowers CR, Parmar SCytotherapyAllogeneic cord blood regulatory T cells can resolve lung inflammation. Cytotherapy. 2023 03; 25(3):245-253.Cytotherapy2022-11-24T00:00:002022Allogeneic cord blood regulatory T cells can resolve lung inflammation.Authorship 10661291436961352Gladstone DE, D'Alessio F, Howard C, Lyu MA, Mock JR, Gibbs KW, Abrams D, Huang M, Zeng K, Herlihy JP, Castillo ST, Bassett R, Sadeghi T, Parmar S, Flowers CR, Mukherjee S, Schoenfeld D, Thall PF, Slutsky ASBlood advancesRandomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS. Blood Adv. 2023 07 11; 7(13):3075-3079.Blood Adv2023-07-11T00:00:002023Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS.Authorship 10758191337508543Zeng K, Huang M, Lyu MA, Khoury JD, Ahmed S, Patel KK, Dropulic B, Reese-Koc J, Caimi PF, Sadeghi T, Lima M, Flowers CR, Parmar SCellsAdjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells. Cells. 2023 07 18; 12(14).Cells2023-07-18T00:00:002023Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells.Authorship 10779921137736101Lyu MA, Tang X, Khoury JD, Raso MG, Huang M, Zeng K, Nishimoto M, Ma H, Sadeghi T, Flowers CR, Parmar SFrontiers in immunologyAllogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus. Front Immunol. 2023; 14:1217121.Front Immunol2023-09-05T00:00:002023Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.24480547Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJCytotherapyThird-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100.Cytotherapy2013-10-26T00:00:002013Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.25051962Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani KBloodRegulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45.Blood2014-07-22T00:00:002014Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.